NRAS and melanoma: In addition, tovorafenib showed strong and sustained p-ERK suppression in pharmacodynamic studies with BRAF-mutant, BRAF deletion mutation and NRAS-mutant xenograft tumor models and caused tumor regression in large, established BRAF V600 mutant melanoma xenografts in mice, with tumors remaining sensitive to a second dosing cycle [22].